| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 13
| Issue : 4 | Page : 322-328 |
|
|
Nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer Michigan Cancer Foundation-7 cell lines
Riska Prasetiawati1, Syahrul Hidayat2, Adel Zamri3, Muchtaridi Muchtaridi2
1 Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jawa Barat; Department Pharmacy, Faculty of Mathematics and Natural Science, Universitas Garut, West Java, Indonesia
2 Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jawa Barat, Indonesia
3 Department of Chemistry, Faculty of Mathematics and Natural Science, Universitas Riau, Riau, Indonesia
Correspondence Address:
Prof. Muchtaridi Muchtaridi
Jl. Bandung-Sumedang KM 21, Jatinangor 45363, West Java
Indonesia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/japtr.japtr_435_22
|
|
|
Hydrazine is an alkaline reduction compound which is widely used in synthesis. Based on the structure–activity analysis, to elicit antitumor activity, the presence of the N-methyl group is an absolute requirement. The aim of the research is to synthesize a new hydrazine derivate compound that has potency as a novel anti-breast cancer. 4-hydrazinylphenyl benzenesulfonate was synthesized employing reduction and diazotization methods. Structure characterization was carried out using Fourier transform infrared (FTIR), C13-nuclear magnetic resonance (NMR), H1-NMR, and High Resolution Time-of-Flight Mass Spectrometry (HR-TOF-MS). The anti-cancer activity of this compound against breast cancer Michigan Cancer Foundation-7 (MCF-7) cell line was determined using a PrestoBlue viability assay. The new of hydrazine derivative, 4-hydrazinylphenyl benzenesulfonate, has been successfully synthesized. The reduction and diazotization methods have been successfully used in the synthesis of new compound of hydrazine derivatives. Structure characterization of 4-hydrazinylphenyl benzenesulfonate was established using FTIR, C13-NMR, H1-NMR, and HR-TOF-MS. The anti-cancer activity of this compound against breast cancer MCF-7 cell line was determined using a PrestoBlue viability assay with IC50 0.00246 μg/mL or 9.32 nM. In conclusion, 4-hydrazinylphenyl benzenesulfonate was successfully synthesized as a new candidate for anti-breast cancer compound.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Next article
